Angiogenesis is another well-known mechanism involved in IPF, which is targeted by Nintedanib, an anti-angiogenesis molecule used in human for its properties against the vascular endothelial growth factor (VEGF) pathway (41). Here, VEGFA is linked to idiopathic pulmonary fibrosis.